Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Internal Medicine, University of North Carolina at Chapel Hill School of Medicine 1994 - 1996
  • Intern, Internal Medicine, University of North Carolina at Chapel Hill School of Medicine 1993 - 1994
  • M.D., University of Virginia 1993
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2018 - 2019
  • Associate Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2010 - 2017
  • Assistant Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2006 - 2010
  • Assistant Clinical Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2002 - 2006
  • Associate in the Department of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 1998 - 2001
• Research
• 

  Selected Grants

  • EMPA-KIDNEY Trial awarded by University of Oxford 2018 - 2022
  • Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) awarded by The George Washington University 2012 - 2019
  • Endocrinology and Metabolism Training Program awarded by National Institutes of Health 2014 - 2019
  • Hostility, PTSD and Physical Health Risk Factors awarded by National Institutes of Health 2009 - 2015
• 

  Fellowships, Supported Research, & Other Grants

  • COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs). Duke Clinical Research Institute, Duke University Medical Center awarded by Boehringer Ingelheim 2018
  • EMPA-KIDNEY. A Multicentre International Randomized Parallel Group Double-Blind Placebo-Controlled Clinical Trial of Empagliflozin Once Daily To Assess Cardio-Renal Outcomes in Patients With Chronic Kidney Disease awarded by Boehringer Ingelheim/University of Oxford 2017
  • Predictive Algorithm and Reinforcement Learning for Diabetes Management: (PEARL-DM) awarded by DCRI Innovation Grant/Duke Forge 2017
  • Consolidated Sotagliflozin Study Program (SOTA) Non-CV Outcomes awarded by Sanofi 2017
  • American Heart Association (AHA) SFRN/Duke Clinical Research Institute Heart failure Center. Project: Improving Population Health for Patients with Diabetes and Heart Failure. Duke University Medical Center, Durham, North Carolina awarded by AHA 2016
  • Advanced Clinical Trials to Test Artificial Pancreas (AP) Device Systems in Type 1 Diabetes (UC4). NIDDK Cooperative Agreement awarded by NIDDK 2016
  • Albiglutide Phase IV HARMONY Outcomes Trial Protocol GLP116174 awarded by GSK 2015
  • Vitamin D and Type 2 Diabetes Study (D2d) awarded by NIDDK 2013
  • Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Duke University Medical Center, Durham, North Carolina awarded by NIDDK 2012
  • The EXSCEL Trial. A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus awarded by AstraZeneca/BMS 2009
  • TECOS: A Phase III, Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus awarded by Merck 2008
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Guimarães, Patrícia O., Eric D. Peterson, Susanna R. Stevens, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Rury R. Holman, and Renato D. Lopes. “Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes..” Int J Cardiol, April 30, 2019. https://doi.org/10.1016/j.ijcard.2019.04.085.
       Full Text  Link to Item
    • Montvida, O., J. B. Green, J. Atherton, and S. K. Paul. “Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes..” Diabetic Medicine : A Journal of the British Diabetic Association 36, no. 4 (April 2019): 491–98. https://doi.org/10.1111/dme.13835.
       Full Text
    • Fanaroff, Alexander C., Robert Clare, Karen S. Pieper, Kenneth W. Mahaffey, Chiara Melloni, Jennifer B. Green, John H. Alexander, et al. “Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials..” Circulation 139, no. 7 (February 2019): 863–73. https://doi.org/10.1161/circulationaha.118.037202.
       Full Text
    • McHugh, Kelly, Adam D. DeVore, Jingjing Wu, Roland A. Matsouaka, Gregg C. Fonarow, Paul A. Heidenreich, Clyde W. Yancy, Jennifer B. Green, Natasha Altman, and Adrian F. Hernandez. “Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review..” Journal of the American College of Cardiology 73, no. 5 (February 2019): 602–11. https://doi.org/10.1016/j.jacc.2018.11.033.
       Full Text
    • Bethel, M Angelyn, Samuel S. Engel, Susanna R. Stevens, Yuliya Lokhnygina, Jie Ding, Robert G. Josse, Michael Alvarsson, et al. “Progression of glucose-lowering diabetes therapy in TECOS..” Endocrinology, Diabetes & Metabolism 2, no. 1 (January 2019). https://doi.org/10.1002/edm2.53.
       Full Text
    • Herrington, William G., David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J. Hauske, Jyothis T. George, et al. “The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study..” Clinical Kidney Journal 11, no. 6 (December 2018): 749–61. https://doi.org/10.1093/ckj/sfy090.
       Full Text
    • Hernandez, Adrian F., Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, Christopher B. Granger, Nigel P. Jones, Lawrence A. Leiter, et al. “Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial..” Lancet (London, England) 392, no. 10157 (October 2, 2018): 1519–29. https://doi.org/10.1016/s0140-6736(18)32261-x.
       Full Text
    • Alfredsson, Joakim, Jennifer B. Green, Susanna R. Stevens, Shelby D. Reed, Paul W. Armstrong, M. Angelyn Bethel, Samuel S. Engel, et al. “Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS..” Diabetes, Obesity & Metabolism 20, no. 10 (October 2018): 2379–88. https://doi.org/10.1111/dom.13377.
       Full Text
    • DeVore, Adam D., and Jennifer B. Green. “Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?.” Jacc. Heart Failure 6, no. 10 (October 2018): 831–32. https://doi.org/10.1016/j.jchf.2018.07.014.
       Full Text
    • McHugh, Kelly R., Adam D. DeVore, Robert J. Mentz, Daniel Edmonston, Jennifer B. Green, and Adrian F. Hernandez. “The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes..” Clinical Cardiology 41, no. 9 (September 21, 2018): 1259–67. https://doi.org/10.1002/clc.23054.
       Full Text
    • Green, Jennifer B., Adrian F. Hernandez, Ralph B. D’Agostino, Chris B. Granger, Salim Janmohamed, Nigel P. Jones, Lawrence A. Leiter, et al. “Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics..” American Heart Journal 203 (September 2018): 30–38. https://doi.org/10.1016/j.ahj.2018.03.030.
       Full Text
    • Reed, Shelby D., Yanhong Li, Jose Leal, Larry Radican, Amanda I. Adler, Joakim Alfredsson, John B. Buse, et al. “Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)..” Diabetes, Obesity & Metabolism 20, no. 7 (July 2018): 1732–39. https://doi.org/10.1111/dom.13292.
       Full Text
    • Wittbrodt, Eric T., James M. Eudicone, Kelly F. Bell, Devin M. Enhoffer, Keith Latham, and Jennifer B. Green. “Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population..” The American Journal of Managed Care 24, no. 8 Suppl (April 2018): S138–45.
    • Wittbrodt, Eric T., James M. Eudicone, Kelly F. Bell, Devin M. Enhoffer, Keith Latham, and Jennifer B. Green. “Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population..” Am J Manag Care 24, no. 8 Suppl (April 2018): S146–55.
       Link to Item
    • Standl, Eberhard, Susanna R. Stevens, Paul W. Armstrong, John B. Buse, Juliana C. N. Chan, Jennifer B. Green, John M. Lachin, et al. “Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype..” Diabetes Care 41, no. 3 (March 2018): 596–603. https://doi.org/10.2337/dc17-1778.
       Full Text
    • Cefalu, William T., Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, et al. “Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum..” Diabetes Care 41, no. 1 (January 2018): 14–31. https://doi.org/10.2337/dci17-0057.
       Full Text
    • Sharma, Abhinav, Jennifer B. Green, Allison Dunning, Yuliya Lokhnygina, Sana M. Al-Khatib, Renato D. Lopes, John B. Buse, et al. “Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial..” Diabetes Care 40, no. 12 (December 2017): 1763–70. https://doi.org/10.2337/dc17-1091.
       Full Text  Link to Item
    • Butler, Javed, Carine E. Hamo, Gerasimos Filippatos, Stuart J. Pocock, Richard A. Bernstein, Martina Brueckmann, Alfred K. Cheung, et al. “The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors..” European Journal of Heart Failure 19, no. 11 (November 2017): 1390–1400. https://doi.org/10.1002/ejhf.933.
       Full Text
    • Navar, Ann Marie, Dianne S. Gallup, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Paul W. Armstrong, John B. Buse, et al. “Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin..” Hypertension (Dallas, Tex. : 1979) 70, no. 5 (November 2017): 907–14. https://doi.org/10.1161/HYPERTENSIONAHA.117.09482.
       Full Text
    • Herbst, Rebecca, Wilburn Bolton, Afreen Shariff, and Jennifer B. Green. “Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions..” Current Diabetes Reports 17, no. 9 (September 2017). https://doi.org/10.1007/s11892-017-0898-8.
       Full Text
    • Pagidipati, Neha J., Ann Marie Navar, Karen S. Pieper, Jennifer B. Green, M Angelyn Bethel, Paul W. Armstrong, Robert G. Josse, et al. “Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)..” Circulation 136, no. 13 (September 2017): 1193–1203. https://doi.org/10.1161/CIRCULATIONAHA.117.027252.
       Full Text
    • Bethel, M Angelyn, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, et al. “Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)..” Diabetes Care 40, no. 4 (April 2017): 494–501. https://doi.org/10.2337/dc16-1135.
       Full Text
    • Bethel, M Angelyn, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, et al. “Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” Diabetes Care 40, no. 4 (April 2017): 494–501. https://doi.org/10.2337/dc16-1135.
       Full Text  Link to Item
    • Spratt, Susan E., Katherine Pereira, Bradi B. Granger, Bryan C. Batch, Matthew Phelan, Michael Pencina, Marie Lynn Miranda, et al. “Assessing electronic health record phenotypes against gold-standard diagnostic criteria for diabetes mellitus..” Journal of the American Medical Informatics Association : Jamia 24, no. e1 (April 2017): e121–28. https://doi.org/10.1093/jamia/ocw123.
       Full Text
    • Buse, John B., M Angelyn Bethel, Jennifer B. Green, Susanna R. Stevens, Yuliya Lokhnygina, Pablo Aschner, Carlos Raffo Grado, et al. “Pancreatic Safety of Sitagliptin in the TECOS Study..” Diabetes Care 40, no. 2 (February 2017): 164–70. https://doi.org/10.2337/dc15-2780.
       Full Text
    • Cooper, Lauren B., Xiaojuan Mi, Robert J. Mentz, Jennifer B. Green, Kevin J. Anstrom, Adrian F. Hernandez, and Lesley H. Curtis. “Management of newly treated diabetes in Medicare beneficiaries with and without heart failure..” Clinical Cardiology 40, no. 1 (January 2017): 38–45. https://doi.org/10.1002/clc.22603.
       Full Text
    • Ikeno, Fumiaki, Maria Mori Brooks, Kaori Nakagawa, Min-Kyu Kim, Hideaki Kaneda, Yoshiaki Mitsutake, Helen A. Vlachos, et al. “SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial..” Journal of the American College of Cardiology 69, no. 4 (January 2017): 395–403. https://doi.org/10.1016/j.jacc.2016.10.067.
       Full Text
    • Josse, Robert G., Sumit R. Majumdar, Yinggan Zheng, Amanda Adler, M Angelyn Bethel, John B. Buse, Jennifer B. Green, et al. “Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial..” Diabetes, Obesity & Metabolism 19, no. 1 (January 2017): 78–86. https://doi.org/10.1111/dom.12786.
       Full Text
    • Coch, R. W., and J. B. Green. “Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight..” Nutrition, Metabolism, and Cardiovascular Diseases : Nmcd 26, no. 9 (September 2016): 767–72. https://doi.org/10.1016/j.numecd.2016.06.004.
       Full Text
    • McGuire, Darren K., Frans Van de Werf, Paul W. Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B. Green, M Angelyn Bethel, et al. “Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial..” Jama Cardiology 1, no. 2 (May 2016): 126–35. https://doi.org/10.1001/jamacardio.2016.0103.
       Full Text
    • Barnard, Karen, Wanda C. Lakey, Bryan C. Batch, Karen Chiswell, Asba Tasneem, and Jennifer B. Green. “Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?.” Plos One 11, no. 5 (January 2016). https://doi.org/10.1371/journal.pone.0156068.
       Full Text  Open Access Copy
    • Espeland, Mark A., Jeffery Probstfield, Donald Hire, J Bruce Redmon, Gregory W. Evans, Mace Coday, Cora E. Lewis, et al. “Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions..” American Journal of Hypertension 28, no. 8 (August 2015): 995–1009. https://doi.org/10.1093/ajh/hpu292.
       Full Text
    • Green, Jennifer B., M Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, et al. “Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes..” The New England Journal of Medicine 373, no. 3 (July 2015): 232–42. https://doi.org/10.1056/nejmoa1501352.
       Full Text
    • Green, Jennifer B. “Update in endocrinology: evidence published in 2014..” Annals of Internal Medicine 162, no. 9 (May 2015): W91–95. https://doi.org/10.7326/m15-0153.
       Full Text
    • Bethel, M. A., J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, and R. R. TECOS Executive Committee. “Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)..” Diabetes, Obesity & Metabolism 17, no. 4 (April 2015): 395–402. https://doi.org/10.1111/dom.12441.
       Full Text
    • Bethel, M. A., J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, et al. “Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” Diabetes, Obesity and Metabolism 17, no. 4 (April 1, 2015): 395–402. https://doi.org/10.1111/dom.12441.
       Full Text
    • Koshizaka, Masaya, Renato D. Lopes, Eric M. Reyes, C Michael Gibson, Phillip J. Schulte, Gail E. Hafley, Adrian F. Hernandez, et al. “Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial..” American Heart Journal 169, no. 1 (January 2015): 175–84. https://doi.org/10.1016/j.ahj.2014.10.013.
       Full Text
    • Magee, M. F., J. E. Tamis-Holland, J. Lu, V. A. Bittner, M. M. Brooks, N. Lopes, A. K. Jacobs, et al. “Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D trial.” International Journal of Endocrinology 2015 (January 1, 2015). https://doi.org/10.1155/2015/610239.
       Full Text
    • Green, Jennifer B. “Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox..” Postgraduate Medicine 126, no. 3 (May 2014): 190–204. https://doi.org/10.3810/pgm.2014.05.2767.
       Full Text
    • Ismail-Beigi, F., M. S. Lombardero, J. Escobedo, S. Genuth, J. Green, E. Massaro, A. D. Mooradian, F. Ovalle, F. Whitehouse, and J. Zonszein. “Determinants of successful glycemic control among participants in the BARI 2D Trial: A Post-hoc Analysis.” Journal of Diabetes and Its Complications 28, no. 1 (2014): 101–9. https://doi.org/10.1016/j.jdiacomp.2013.01.006.
       Full Text
    • Ismail-Beigi, Faramarz, Manuel S. Lombardero, Jorge Escobedo, Saul Genuth, Jennifer Green, Elaine Massaro, Arshag D. Mooradian, et al. “Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis..” J Diabetes Complications 28, no. 1 (January 2014): 101–9. https://doi.org/10.1016/j.jdiacomp.2013.01.006.
       Full Text  Link to Item
    • Koshizaka, M., R. D. Lopes, E. M. Reyes, C. M. Gibson, P. J. Schulte, G. E. Hafley, A. F. Hernandez, et al. “Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV Trial.” American Heart Journal 169, no. 1 (January 1, 2014): 175–84. https://doi.org/10.1016/j.ahj.2014.10.013.
       Full Text
    • Green, Jennifer B., M Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, and Rury R. Holman. “Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease..” American Heart Journal 166, no. 6 (December 2013): 983-989.e7. https://doi.org/10.1016/j.ahj.2013.09.003.
       Full Text
    • Povsic, Thomas J., Richard Sloane, Jiying Zhou, Carl F. Pieper, Megan P. Pearson, Eric D. Peterson, Jennifer B. Green, Harvey J. Cohen, and Miriam C. Morey. “Lower levels of circulating progenitor cells are associated with low physical function and performance in elderly men with impaired glucose tolerance: a pilot substudy from the VA Enhanced Fitness trial..” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 68, no. 12 (December 2013): 1559–66. https://doi.org/10.1093/gerona/glt067.
       Full Text
    • Povsic, T. J., R. Sloane, J. B. Green, J. Zhou, C. F. Pieper, M. P. Pearson, E. D. Peterson, H. J. Cohen, and M. C. Morey. “Depletion of circulating progenitor cells precedes overt diabetes: A substudy from the VA enhanced fitness trial.” Journal of Diabetes and Its Complications 27, no. 6 (November 1, 2013): 633–36. https://doi.org/10.1016/j.jdiacomp.2013.08.004.
       Full Text
    • Povsic, Thomas J., Richard Sloane, Jennifer B. Green, Jiying Zhou, Carl F. Pieper, Megan P. Pearson, Eric D. Peterson, Harvey J. Cohen, and Miriam C. Morey. “Depletion of circulating progenitor cells precedes overt diabetes: a substudy from the VA enhanced fitness trial..” Journal of Diabetes and Its Complications 27, no. 6 (November 2013): 633–36. https://doi.org/10.1016/j.jdiacomp.2013.08.004.
       Full Text
    • Pop-Busui, Rodica, Jiang Lu, Maria Mori Brooks, Stewart Albert, Andrew D. Althouse, Jorge Escobedo, Jenifer Green, et al. “Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort..” Diabetes Care 36, no. 10 (October 2013): 3208–15. https://doi.org/10.2337/dc13-0012.
       Full Text  Link to Item
    • Green, Jennifer B. “Diabetes trials: is an ounce of prevention enough?.” Expert Review of Endocrinology & Metabolism 8, no. 5 (September 2013): 419–21. https://doi.org/10.1586/17446651.2013.827382.
       Full Text
    • Lakey, W. C., K. Barnard, B. C. Batch, K. Chiswell, A. Tasneem, and J. B. Green. “Are current clinical trials in diabetes addressing important issues in diabetes care?.” Diabetologia 56, no. 6 (June 2013): 1226–35. https://doi.org/10.1007/s00125-013-2890-4.
       Full Text
    • Green, J. B., M. A. Bethel, S. K. Paul, A. Ring, K. D. Kaufman, D. R. Shapiro, R. M. Califf, and R. R. Holman. “Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.” American Heart Journal 166, no. 6 (January 1, 2013). https://doi.org/10.1016/j.ahj.2013.09.003.
       Full Text
    • Lakey, W. C., K. Barnard, B. C. Batch, K. Chiswell, A. Tasneem, and J. B. Green. “Are current clinical trials in diabetes addressing important issues in diabetes care?.” Diabetologia 56, no. 6 (2013): 1226–35. https://doi.org/10.1007/s00125-013-2890-4.
       Full Text
    • Green, J. B., W. Lakey, K. Barnard, B. Batch, M. Bethel, K. Chiswell, and A. Tasneem. “State of diabetes-related trials in the clinicaltrials.gov dataset.” Diabetologia 55 (October 1, 2012): S90–91.
       Link to Item
    • Morey, M. C., C. F. Pieper, D. E. Edelman, W. S. Yancy Jr, J. B. Green, H. Lum, M. J. Peterson, et al. “Enhanced fitness: a randomized controlled trial of the effects of home-based physical activity counseling on glycemic control in older adults with prediabetes mellitus..” Journal of the American Geriatrics Society 60, no. 9 (September 2012): 1655–62. https://doi.org/10.1111/j.1532-5415.2012.04119.x.
       Full Text
    • Green, Jennifer B. “The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety..” Postgraduate Medicine 124, no. 4 (July 2012): 54–61. https://doi.org/10.3810/pgm.2012.07.2566.
       Full Text
    • Schwartz, Ann V., Karen L. Margolis, Deborah E. Sellmeyer, Eric Vittinghoff, Walter T. Ambrosius, Denise E. Bonds, Robert G. Josse, et al. “Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial..” Diabetes Care 35, no. 7 (July 2012): 1525–31. https://doi.org/10.2337/dc11-2184.
       Full Text
    • Stiles, Monica C., Elizabeth R. Seaquist, Jean Francois Yale, Jennifer B. Green, Lois Anne Katz, Sarah Kempainen, Laney S. Light, Patricia V. Pepper, Zhu-Ming Zhang, and Elsayed Z. Soliman. “Is silent myocardial infarction more common in women with type 2 diabetes than in men?.” Journal of Diabetes and Its Complications 26, no. 2 (March 24, 2012): 118–22. https://doi.org/10.1016/j.jdiacomp.2012.02.002.
       Full Text
    • Koshizaka, Masaya, Jennifer B. Green, and John H. Alexander. “Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?.” Circulation Journal : Official Journal of the Japanese Circulation Society 76, no. 7 (January 2012): 1572–80. https://doi.org/10.1253/circj.cj-12-0428.
       Full Text
    • Hall, K. S., C. F. Pieper, D. E. Edelman, W. S. Yancy Jr, J. B. Green, H. Lum, M. J. Peterson, et al. “Lessons learned when innovations go awry: a baseline description of a behavioral trial-the Enhancing Fitness in Older Overweight Veterans with Impaired Fasting Glucose study..” Translational Behavioral Medicine 1, no. 4 (November 2011): 573–87. https://doi.org/10.1007/s13142-011-0075-6.
       Full Text
    • Buse, John B., George Dailey, Andrew A. Ahmann, Richard M. Bergenstal, Jennifer B. Green, Tim Peoples, Robert J. Tanenberg, and Qingqing Yang. “Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience..” Diabetes Technology & Therapeutics 13, no. 6 (June 2011): 601–6. https://doi.org/10.1089/dia.2010.0225.
       Full Text
    • Chen, Louis C., and Jennifer B. Green. “First reported case of unilateral Graves' disease in the left lobe of a bilobar thyroid gland..” Thyroid : Official Journal of the American Thyroid Association 21, no. 6 (June 2011): 683–86. https://doi.org/10.1089/thy.2010.0343.
       Full Text
    • Jiang, Wei, Shelby Ladd, Carolyn Martsberger, Mark Feinglos, Susan E. Spratt, Maragatha Kuchibhatla, Jennifer Green, and Ranga Krishnan. “Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy..” Journal of Clinical Psychopharmacology 31, no. 2 (April 2011): 207–13. https://doi.org/10.1097/jcp.0b013e31820f4f57.
       Full Text
    • Barnard, Karen, Mary Elizabeth Cox, and Jennifer B. Green. “Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes..” Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy 3 (October 27, 2010): 363–72. https://doi.org/10.2147/DMSOTT.S10195.
       Full Text
    • Cox, Mary Elizabeth, Jennifer Rowell, Leonor Corsino, and Jennifer B. Green. “Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy..” Drug, Healthcare and Patient Safety 2 (January 28, 2010): 7–19.
    • Corsino, Leonor, Mary Elizabeth Cox, Jennifer Rowel, and Jennifer B. Green. “Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes..” Clinical Medicine. Therapeutics 1 (August 2009): 1103–19.
    • Pop-Busui, Rodica, Manuel Lombardero, Victor Lavis, Alan Forker, Jennifer Green, Mary Korytkowski, Burton E. Sobel, Teresa L. Z. Jones, and Teresa L. Z. BARI 2D Study Group. “Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study)..” The American Journal of Cardiology 104, no. 1 (July 2009): 52–58. https://doi.org/10.1016/j.amjcard.2009.02.046.
       Full Text
    • Gerstein, H. C., M. E. Miller, R. P. Byington, D. C. Goff, J. T. Bigger, J. B. Buse, W. C. Cushman, et al. “Effects of intensive glucose lowering in type 2 diabetes.” New England Journal of Medicine 358, no. 24 (June 12, 2008): 2545–59. https://doi.org/10.1056/NEJMoa0802743.
       Full Text
    • Green, Jennifer, and Mark Feinglos. “New combination treatments in the management of diabetes: focus on sitagliptin-metformin..” Vascular Health and Risk Management 4, no. 4 (January 2008): 743–51. https://doi.org/10.2147/vhrm.s3105.
       Full Text
    • Green, Jennifer B., and Mark N. Feinglos. “Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity..” Current Diabetes Reports 7, no. 5 (October 2007): 369–75. https://doi.org/10.1007/s11892-007-0060-0.
       Full Text
    • Green, J., and M. Feinglos. “Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm..” Int J Clin Pract Suppl, no. 154 (August 2007): 3–11. https://doi.org/10.1111/j.1742-1241.2007.01438.x.
       Full Text  Link to Item
    • Green, J., and M. Feinglos. “Update on type 2 diabetes mellitus: Understanding changes in the diabetes treatment paradigm.” International Journal of Clinical Practice, Supplement 61, no. 154 (August 1, 2007): 3–11. https://doi.org/10.1111/j.1742-1241.2007.01438.x.
       Full Text
    • Buse, J. B., W. T. Friedewald, J. T. Bigger, R. P. Byington, W. C. Cushman, S. Genuth, H. C. Gerstein, et al. “Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods.” American Journal of Cardiology 99, no. 12 (June 18, 2007). https://doi.org/10.1016/j.amjcard.2007.03.003.
       Full Text
    • Green, Jennifer B., and Mark N. Feinglos. “Are sulfonylureas passé?.” Current Diabetes Reports 6, no. 5 (November 2006): 373–77. https://doi.org/10.1007/s11892-006-0008-9.
       Full Text
    • Weber, T. J., J. B. Green, H. Chow, A. Spitz, and G. S. Wagner. “How bone density testing influenced osteoporosis treatment in a community hospital..” North Carolina Medical Journal 61, no. 6 (November 2000): 321–24.

  • Book Sections

    • Green, J. B. “Disorders of monosaccharide metabolism.” In Garner and Klintworth’s Pathobiology of Ocular Disease Part B, Third Edition, 1005–18, 2007.

  • Conference Papers

    • Shavadia, Jay, Yinggan Zheng, Jennifer B. Green, Paul Armstrong, Cynthia Westerhout, Darren McGuire, Matthew Roe, J. H. Cornel, Rury Holman, and Eric D. Peterson. “ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY.” In Journal of the American College of Cardiology, 73:138–138. Elsevier BV, 2019. https://doi.org/10.1016/s0735-1097(19)30746-6.
       Full Text
    • De Ferrari, G. M., S. R. Stevens, G. Ambrosio, S. Leonardi, D. K. McGuire, P. W. Armstrong, J. B. Green, M. A. Bethel, R. R. Holman, and E. D. Peterson. “LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS.” In European Heart Journal, 39:399–400. OXFORD UNIV PRESS, 2018.
       Link to Item
    • McHugh, Kelly, JingJing Wu, Roland A. Matsouaka, Adam D. DeVore, Gregg C. Fonarow, Paul A. Heidenreich, Clyde W. Yancy, Jennifer B. Green, Natasha Altman, and Adrian F. Hernandez. “Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry.” In Journal of Cardiac Failure, 24:S92–S92. Elsevier BV, 2018. https://doi.org/10.1016/j.cardfail.2018.07.358.
       Full Text
    • Sharma, A., Y. Zheng, J. A. Ezekowitz, C. M. Westerhout, S. G. Goodman, P. W. Armstrong, J. B. Buse, et al. “Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine.” In European Heart Journal, 39:871–871. OXFORD UNIV PRESS, 2018.
       Link to Item
    • Engel, S. S., M. A. Bethel, J. Garg, S. R. Stevens, Y. Lokhnygina, R. G. Josse, J. B. Green, E. D. Peterson, and R. R. Holman. “Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS).” In Diabetologia, 60:S3–S3. SPRINGER, 2017.
       Link to Item
    • Gray, A. M., J. Leal, S. D. Reed, Y. Li, F. Graham, J. B. Green, K. D. Kaufman, et al. “Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” In Diabetologia, 60:S357–S357. SPRINGER, 2017.
       Link to Item
    • Paul, S., J. B. Green, J. Atherton, and O. Montvida. “Risk of pancreatic diseases by second-line anti diabetes drug class: real world based evidence.” In Diabetologia, 60:S69–70. SPRINGER, 2017.
       Link to Item
    • Pagidipati, N., Y. Zheng, J. B. Green, D. K. Mcguire, R. J. Mentz, S. Shah, P. Aschner, et al. “The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial.” In European Heart Journal, 38:608–608. OXFORD UNIV PRESS, 2017.
       Link to Item
    • Green, J. B., J. Alfredsson, S. R. Stevens, S. D. Reed, D. K. McGuire, P. W. Armstrong, S. S. Engel, et al. “Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” In Diabetologia, 59:S544–45. SPRINGER, 2016.
       Link to Item
    • Josse, R. G., S. R. Majumdar, Y. Zheng, J. B. Buse, J. B. Green, K. D. Kaufman, E. D. Peterson, R. R. Holman, and P. W. Armstrong. “Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial.” In Diabetologia, 59:S372–S372. SPRINGER, 2016.
       Link to Item
    • Lee, S. W., J. B. Welsh, J. B. Green, C. Joyce, W. V. Tamborlane, and F. R. Kaufman. “Successful transitions from MDI therapy to sensor-augmented pump therapy in the STAR 3 study: system settings and behaviours.” In Diabetologia, 54:S395–96. SPRINGER, 2011.
       Link to Item
    • Calles-Escandon, J., L. Light, L. Lovato, A. Getaneh, D. Simmons, J. Kirk, D. Bonds, et al. “Glycaemia management of minority participants in ACCORD.” In Diabetologia, 53:S19–S19. SPRINGER, 2010.
       Link to Item
    • Green, J. B., A. Ahmann, R. M. Bergenstal, G. Dailey, R. Tanenberg, and J. B. Buse. “Glucose control in adults during a 1-year randomised controlled trial comparing sensor-augmented pump therapy and multiple daily injection therapy: STAR 3 study.” In Diabetologia, 53:S24–S24. SPRINGER, 2010.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.